
TORONTO, July 31 /CNW/ - Patheon Inc. (TSX: PTI) today announced that it reached agreement with its lenders under its North American credit facilities to amend the credit agreement following the Company's announcement on July 24, 2006 with respect to its Q3 results. In the coming weeks, the Company will also be discussing with its lenders further amendments that give the Company more financial flexibility as its implements its previously announced performance enhancement program. About Patheon Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug development and manufacturing services to the international pharmaceutical industry. Patheon operates a network of 14 facilities in the United States, Canada and Europe, employing 6,100 people and serving a client base of more than 200 pharmaceutical and biotechnology companies. Forward-Looking Statements This news release contains forward-looking statements with respect to Patheon, including its business operations and strategy and financial performance and condition. Although management believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from expectations include, but are not limited to, currency fluctuations, the level of outsourcing services required by the pharmaceutical companies (and in particular our clients), the impact of changes in pharmaceutical development and manufacturing regulations and general economic and market factors (including inflation and changes in laws) and other factors discussed in materials filed with applicable securities regulatory authorities from time to time. %SEDAR: 00001700E